Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 22;10(2):239–250. doi: 10.1002/sctm.20-0181

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. stem cells translational medicine published by Wiley Periodicals LLC on behalf of AlphaMed Press.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Statistical analysis of final DeepNEU predictions of anti‐COVID‐19 efficacy for repurposed drugs. The paired two‐tailed t test was used to evaluate the effects of each treatment on viral (A) genotypic profile and (B) genotypic profiles compared with the aiLUNG (wild‐type) profiles. The data from three independent experiments were used to conduct this analysis. The level of significance was set at P < .05 for all comparisons. The analysis also indicated that overall, the two drug combinations (N = 6) outperformed the single drug treatments (N = 4) based on the genotypic profiles (P < .01). Based on the phenotypic profiles, no significant differences were seen (P > .05)